ORIC PHARMACEUTICALS, INC. Increase (Decrease) in Accounts Payable and Accrued Liabilities
ORIC PHARMACEUTICALS, INC. (ORIC) reported Increase (Decrease) in Accounts Payable and Accrued Liabilities of -$1.10 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-03.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities · last filed 2026-08-03
- ORIC PHARMACEUTICALS, INC. increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2026-06-30 was $2.22M.
- ORIC PHARMACEUTICALS, INC. increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2026-03-31 was -$3.32M.
- ORIC PHARMACEUTICALS, INC. increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2025-12-31 was -$448.00K, a 114.81% decline year-over-year.
- ORIC PHARMACEUTICALS, INC. increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2025-09-30 was $1.36M, a 79.79% increase year-over-year.
- ORIC PHARMACEUTICALS, INC. increase (decrease) in accounts payable and accrued liabilities for fiscal 2025 was -$7.25M, a 497.04% decline from fiscal 2024.
- ORIC PHARMACEUTICALS, INC. increase (decrease) in accounts payable and accrued liabilities for fiscal 2024 was $1.82M, a 44.33% decline from fiscal 2023.
- ORIC PHARMACEUTICALS, INC. increase (decrease) in accounts payable and accrued liabilities for fiscal 2023 was $3.28M.
- ORIC PHARMACEUTICALS, INC. increase (decrease) in accounts payable and accrued liabilities for fiscal 2022 was -$1.48M, a 150.32% decline from fiscal 2021.
| Period end | Increase (Decrease) in Accounts Payable and Accrued Liabilities 3 month | Increase (Decrease) in Accounts Payable and Accrued Liabilities 6 month | Increase (Decrease) in Accounts Payable and Accrued Liabilities 9 month | Increase (Decrease) in Accounts Payable and Accrued Liabilities 12 month |
|---|---|---|---|---|
| 2026-06-30 | $2.22M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-03 | -$1.10M 10-Q · filed 2026-08-03 | -$1.55M derived: sum of 3 quarters · filed 2026-08-03 | -$189.00K derived: sum of 4 quarters · filed 2026-08-03 |
| 2026-03-31 | -$3.32M 10-Q · filed 2026-05-04 | -$3.77M derived: sum of 2 quarters · filed 2026-05-04 | -$2.41M derived: sum of 3 quarters · filed 2026-05-04 | -$2.66M derived: sum of 4 quarters · filed 2026-08-03 |
| 2025-12-31 | -$448.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-23 | $913.00K derived: sum of 2 quarters · filed 2026-02-23 | $665.00K derived: sum of 3 quarters · filed 2026-08-03 | -$7.25M 10-K · filed 2026-02-23 |
| 2025-09-30 | $1.36M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $1.11M derived: sum of 2 quarters · filed 2026-08-03 | -$6.80M 10-Q · filed 2025-11-13 | -$3.77M derived: sum of 4 quarters · filed 2026-08-03 |
| 2025-06-30 | -$248.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-03 | -$8.16M 10-Q · filed 2026-08-03 | -$5.13M derived: sum of 3 quarters · filed 2026-08-03 | -$4.38M derived: sum of 4 quarters · filed 2026-08-03 |
| 2025-03-31 | -$7.91M 10-Q · filed 2026-05-04 | -$4.88M derived: sum of 2 quarters · filed 2026-05-04 | -$4.13M derived: sum of 3 quarters · filed 2026-05-04 | -$328.00K derived: sum of 4 quarters · filed 2026-05-04 |
| 2024-12-31 | $3.03M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-23 | $3.78M derived: sum of 2 quarters · filed 2026-02-23 | $7.58M derived: sum of 3 quarters · filed 2026-02-23 | $1.82M 10-K · filed 2026-02-23 |
| 2024-09-30 | $757.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $4.56M derived: sum of 2 quarters · filed 2025-11-13 | -$1.20M 10-Q · filed 2025-11-13 | -$222.00K derived: sum of 4 quarters · filed 2025-11-13 |
| 2024-06-30 | $3.80M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-12 | -$1.96M 10-Q · filed 2025-08-12 | -$979.00K derived: sum of 3 quarters · filed 2025-08-12 | $2.93M derived: sum of 4 quarters · filed 2025-08-12 |
| 2024-03-31 | -$5.76M 10-Q · filed 2025-05-05 | -$4.78M derived: sum of 2 quarters · filed 2025-05-05 | -$868.00K derived: sum of 3 quarters · filed 2025-05-05 | -$1.69M derived: sum of 4 quarters · filed 2025-05-05 |
| 2023-12-31 | $979.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-18 | $4.89M derived: sum of 2 quarters · filed 2025-02-18 | $4.07M derived: sum of 3 quarters · filed 2025-02-18 | $3.28M 10-K · filed 2025-02-18 |
| 2023-09-30 | $3.91M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | $3.09M derived: sum of 2 quarters · filed 2024-11-12 | $2.30M 10-Q · filed 2024-11-12 | $3.74M derived: sum of 4 quarters · filed 2024-11-12 |
| 2023-06-30 | -$820.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-12 | -$1.61M 10-Q · filed 2024-08-12 | -$168.00K derived: sum of 3 quarters · filed 2024-08-12 | $332.00K derived: sum of 4 quarters · filed 2024-08-12 |
| 2023-03-31 | -$792.00K 10-Q · filed 2024-05-06 | $652.00K derived: sum of 2 quarters · filed 2024-05-06 | $1.15M derived: sum of 3 quarters · filed 2024-05-06 | $994.00K derived: sum of 4 quarters · filed 2024-05-06 |
| 2022-12-31 | $1.44M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-11 | $1.94M derived: sum of 2 quarters · filed 2024-03-11 | $1.79M derived: sum of 3 quarters · filed 2024-03-11 | -$1.48M 10-K · filed 2024-03-11 |
| 2022-09-30 | $500.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-06 | $342.00K derived: sum of 2 quarters · filed 2023-11-06 | -$2.92M 10-Q · filed 2023-11-06 | -$440.00K derived: sum of 4 quarters · filed 2023-11-06 |
| 2022-06-30 | -$158.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | -$3.42M 10-Q · filed 2023-08-10 | -$940.00K derived: sum of 3 quarters · filed 2023-08-10 | $697.00K derived: sum of 4 quarters · filed 2023-08-10 |
| 2022-03-31 | -$3.26M 10-Q · filed 2023-05-08 | -$782.00K derived: sum of 2 quarters · filed 2023-05-08 | $855.00K derived: sum of 3 quarters · filed 2023-05-08 | $2.91M derived: sum of 4 quarters · filed 2023-05-08 |
| 2021-12-31 | $2.48M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-16 | $4.12M derived: sum of 2 quarters · filed 2023-03-16 | $6.17M derived: sum of 3 quarters · filed 2023-03-16 | $2.93M 10-K · filed 2023-03-16 |
| 2021-09-30 | $1.64M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-07 | $3.69M derived: sum of 2 quarters · filed 2022-11-07 | $452.00K 10-Q · filed 2022-11-07 | $2.48M derived: sum of 4 quarters · filed 2022-11-07 |
| 2021-06-30 | $2.05M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | -$1.19M 10-Q · filed 2022-08-11 | $847.00K derived: sum of 3 quarters · filed 2022-08-11 | $1.74M derived: sum of 4 quarters · filed 2022-08-11 |
| 2021-03-31 | -$3.24M 10-Q · filed 2022-05-09 | -$1.21M derived: sum of 2 quarters · filed 2022-05-09 | -$310.00K derived: sum of 3 quarters · filed 2022-05-09 | $1.30M derived: sum of 4 quarters · filed 2022-05-09 |
| 2020-12-31 | $2.03M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-21 | $2.93M derived: sum of 2 quarters · filed 2022-03-21 | $4.54M derived: sum of 3 quarters · filed 2022-03-21 | $4.30M 10-K · filed 2022-03-21 |
| 2020-09-30 | $896.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-08 | $2.51M derived: sum of 2 quarters · filed 2021-11-08 | $2.27M 10-Q · filed 2021-11-08 | $2.75M derived: sum of 4 quarters · filed 2022-03-21 |
| 2020-06-30 | $1.61M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-10 | $1.38M 10-Q · filed 2021-08-10 | $1.86M derived: sum of 3 quarters · filed 2022-03-21 | $2.15M derived: sum of 4 quarters · filed 2022-03-21 |
| 2020-03-31 | -$237.00K 10-Q · filed 2021-05-06 | $245.00K derived: sum of 2 quarters · filed 2022-03-21 | $537.00K derived: sum of 3 quarters · filed 2022-03-21 | $409.00K derived: sum of 4 quarters · filed 2022-03-21 |
| 2019-12-31 | $482.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-21 | $774.00K derived: sum of 2 quarters · filed 2022-03-21 | $646.00K derived: sum of 3 quarters · filed 2022-03-21 | $986.00K 10-K · filed 2022-03-21 |
| 2019-09-30 | $292.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-05 | $164.00K derived: sum of 2 quarters · filed 2020-11-05 | $504.00K 10-Q · filed 2020-11-05 | |
| 2019-06-30 | -$128.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-05 | $212.00K 10-Q · filed 2020-08-05 | ||
| 2019-03-31 | $340.00K 10-Q · filed 2020-05-20 | |||
| 2018-12-31 | -$410.00K 10-K · filed 2021-03-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kardigan, Inc. (KARD) | United States | $1.346B | |
| Tyra Biosciences, Inc. (TYRA) | United States | $1.337B | -12.83 |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| Damora Therapeutics, Inc. (DMRA) | $1.250B | -6.10 | |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |